RxDoctor Payments Data

Ayesha Bennett

Family · Saint Clair Shores, MINPI 1053895193

Payments from drug & device makers

$3,370in general payments, 2019–2025

Across 148 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$665
  • Sanofi$452
  • GSK$444
  • Takeda Pharmaceuticals U.S.A., Inc.$285
  • Boehringer Ingelheim$259
  • Pfizer$188
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,370 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
Arnuity ElliptaFluticasone Furoate16$3,790
Azelastine Hcl39$1,053
Montelukast Sodium62$990
Albuterol Sulfate HfaAlbuterol Sulfate23$619
Fluticasone Propionate29$455
Famotidine24$341
Hydroxyzine Hcl19$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$444$3,79016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →